6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
to	TO	to	to	to	N	O
XEOMIN	NNS	xeomin	xeomin	xeomin	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
Breathing	NNP	breathing	breathing	breath	N	B-AdverseReaction
Difficulties	NNP	difficulties	difficulty	difficulti	N	I-AdverseReaction
in	IN	in	in	in	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
cervical	JJ	cervical	cervical	cervic	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Spread	NN	spread	spread	spread	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
Effects	NNS	effects	effect	effect	N	I-AdverseReaction
from	IN	from	from	from	N	I-AdverseReaction
Toxin	NNP	toxin	toxin	toxin	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Cervical	JJ	cervical	cervical	cervic	N	O
Dystonia	NNP	dystonia	dystonia	dystonia	Y	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
observed	JJ	observed	observed	observ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
dysphagia	JJ	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neck	RB	neck	neck	neck	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Blepharospasm	NN	blepharospasm	blepharospasm	blepharospasm	Y	O

:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
observed	JJ	observed	observed	observ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
ptosis	NN	ptosis	ptosis	ptosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
eye	NN	eye	eye	eye	N	I-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
visual	JJ	visual	visual	visual	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Glabellar	JJ	glabellar	glabellar	glabellar	N	O
Lines	NNS	lines	line	line	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
observed	JJ	observed	observed	observ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
headache	JJ	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Merz	NNP	merz	merz	merz	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
,	,	,	,	,	N	O
LLC	NNP	llc	llc	llc	N	O
at	IN	at	at	at	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
493	CD	493	493	493	N	O
-	:	-	-	-	N	O
6646	CD	6646	6646	6646	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Cervical	JJ	cervical	cervical	cervic	N	O
Dystonia	NNP	dystonia	dystonia	dystonia	Y	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
intramuscular	NN	intramuscular	intramuscular	intramuscular	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
cervical	JJ	cervical	cervical	cervic	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
159	CD	159	159	159	N	O
patients	NNS	patients	patient	patient	N	O
received	VBN	received	received	receiv	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
(	(	(	(	(	N	O
78	CD	78	78	78	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
a	DT	a	a	a	N	O
total	JJ	total	total	total	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
120	CD	120	120	120	N	O
Units	NNS	units	unit	unit	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
81	CD	81	81	81	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
a	DT	a	a	a	N	O
total	JJ	total	total	total	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
240	CD	240	240	240	N	O
Units	NNS	units	unit	unit	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

XEOMIN	SYM	xeomin	xeomin	xeomin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
18	CD	18	18	18	N	O
to	TO	to	to	to	N	O
79	CD	79	79	79	N	O
years	NNS	years	year	year	N	O
old	JJ	old	old	old	N	O
(	(	(	(	(	N	O
mean	JJ	mean	mean	mean	N	O
53	CD	53	53	53	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
female	JJ	female	female	femal	N	O
(	(	(	(	(	N	O
66%	CD	66%	66%	66%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Caucasian	NNP	caucasian	caucasian	caucasian	N	O
(	(	(	(	(	N	O
91%	CD	91%	91%	91%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
study	NN	study	study	studi	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
approximately	RB	approximately	approximately	approxim	N	O
25%	CD	25%	25%	25%	N	O
had	VBD	had	had	had	N	O
mild	VBN	mild	mild	mild	N	O
,	,	,	,	,	N	O
50%	CD	50%	50%	50%	N	O
had	VBD	had	had	had	N	O
moderate	NN	moderate	moderate	moder	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
25%	CD	25%	25%	25%	N	O
had	VBD	had	had	had	N	O
severe	JJ	severe	severe	sever	N	O
cervical	JJ	cervical	cervical	cervic	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
61%	CD	61%	61%	61%	N	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
previously	RB	previously	previously	previous	N	O
received	VBN	received	received	receiv	N	O
another	DT	another	another	anoth	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
type	NN	type	type	type	N	O
A	DT	a	a	a	N	O
product	NN	product	product	product	N	O
.	.	.	.	.	N	O

Common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
)	)	)	)	)	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
(	(	(	(	(	N	O
120	CD	120	120	120	N	O
Units	NNS	units	unit	unit	N	O
or	CC	or	or	or	N	O
240	CD	240	240	240	N	O
Units	NNS	units	unit	unit	N	O
)	)	)	)	)	N	O
included	VBD	included	included	includ	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neck	NN	neck	neck	neck	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
Common	JJ	common	common	common	N	O
TEAEs	NNP	teaes	teaes	teae	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Greater	NNP	greater	greater	greater	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
:	:	:	:	:	N	O
Double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
Blind	IN	blind	blind	blind	Y	O
Phase	NNP	phase	phase	phase	N	O
of	IN	of	of	of	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O

Double	NNP	double	double	doubl	N	O
-	:	-	-	-	N	O
Blind	NNP	blind	blind	blind	Y	O
Phase	NNP	phase	phase	phase	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
ClassPreferred	NNP	classpreferred	classpreferred	classpref	N	O
Term	NNP	term	term	term	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
120	CD	120	120	120	N	O
Units	NNP	units	unit	unit	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
77	CD	77	77	77	N	O
)	)	)	)	)	N	O
XEOMIN	$	xeomin	xeomin	xeomin	N	O
240	CD	240	240	240	N	O
Units	NNP	units	unit	unit	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
82	CD	82	82	82	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
74	CD	74	74	74	N	O
)	)	)	)	)	N	O

Any	DT	any	any	ani	N	O

TEAEs	NNP	teaes	teaes	teae	N	O
57%	CD	57%	57%	57%	N	O
55%	CD	55%	55%	55%	N	O
42%	CD	42%	42%	42%	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
23%	CD	23%	23%	23%	N	O
32%	CD	32%	32%	32%	N	O
11%	CD	11%	11%	11%	N	O

Neck	NNP	neck	neck	neck	N	B-AdverseReaction
pain	VBP	pain	pain	pain	Y	I-AdverseReaction
7%	CD	7%	7%	7%	N	O
15%	CD	15%	15%	15%	N	O
4%	CD	4%	4%	4%	N	O

Muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
7%	CD	7%	7%	7%	N	O
11%	CD	11%	11%	11%	N	O
1%	CD	1%	1%	1%	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
7%	CD	7%	7%	7%	N	O
4%	CD	4%	4%	4%	N	O
1%	CD	1%	1%	1%	N	O

Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
18%	CD	18%	18%	18%	N	O
24%	CD	24%	24%	24%	N	O
4%	CD	4%	4%	4%	N	O

Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
13%	CD	13%	13%	13%	N	O
18%	CD	18%	18%	18%	N	O
3%	CD	3%	3%	3%	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
16%	CD	16%	16%	16%	N	O
17%	CD	17%	17%	17%	N	O
7%	CD	7%	7%	7%	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
16%	CD	16%	16%	16%	N	O
11%	CD	11%	11%	11%	N	O
11%	CD	11%	11%	11%	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
9%	CD	9%	9%	9%	N	O
4%	CD	4%	4%	4%	N	O
7%	CD	7%	7%	7%	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
14%	CD	14%	14%	14%	N	O
13%	CD	13%	13%	13%	N	O
11%	CD	11%	11%	11%	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
13%	CD	13%	13%	13%	N	O
10%	CD	10%	10%	10%	N	O
3%	CD	3%	3%	3%	N	O

Blepharospasm	NN	blepharospasm	blepharospasm	blepharospasm	Y	O

In	IN	in	in	in	N	O

the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
blepharospasm	NN	blepharospasm	blepharospasm	blepharospasm	Y	B-AdverseReaction
previously	RB	previously	previously	previous	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
onabotulinumtoxinA	NN	onabotulinumtoxina	onabotulinumtoxina	onabotulinumtoxina	N	O
(	(	(	(	(	N	O
Botox	NNP	botox	botox	botox	N	O
)	)	)	)	)	N	O
[	VBD	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.2	CD	14.2	14.2	14.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
74	CD	74	74	74	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
approximately	RB	approximately	approximately	approxim	N	O
33	CD	33	33	33	N	O
Units	NNS	units	unit	unit	N	O
per	IN	per	per	per	N	O
eye	NN	eye	eye	eye	N	O
(	(	(	(	(	N	O
minimum	JJ	minimum	minimum	minimum	N	O
10	CD	10	10	10	N	O
Units	NNS	units	unit	unit	N	O
,	,	,	,	,	N	O
maximum	JJ	maximum	maximum	maximum	N	O
50	CD	50	50	50	N	O
Units	NNS	units	unit	unit	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

XEOMIN	SYM	xeomin	xeomin	xeomin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
22	CD	22	22	22	N	O
to	TO	to	to	to	N	O
79	CD	79	79	79	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
(	(	(	(	(	N	O
mean	JJ	mean	mean	mean	N	O
62	CD	62	62	62	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
female	JJ	female	female	femal	N	O
(	(	(	(	(	N	O
65%	CD	65%	65%	65%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Caucasian	NNP	caucasian	caucasian	caucasian	N	O
(	(	(	(	(	N	O
79%	CD	79%	79%	79%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
time	NN	time	time	time	N	O
since	IN	since	since	sinc	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
approximately	RB	approximately	approximately	approxim	N	O
5	CD	5	5	5	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
study	NN	study	study	studi	N	O
were	VBD	were	were	were	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
ptosis	NN	ptosis	ptosis	ptosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
eye	NN	eye	eye	eye	N	I-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
visual	JJ	visual	visual	visual	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
;	:	;	;	;	N	O
one	CD	one	one	one	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patient	NN	patient	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
(	(	(	(	(	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
Common	JJ	common	common	common	N	O
TEAEs	NNP	teaes	teaes	teae	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Greater	NNP	greater	greater	greater	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
:	:	:	:	:	N	O
Double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
Blind	IN	blind	blind	blind	Y	O
Phase	NNP	phase	phase	phase	N	O
of	IN	of	of	of	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O

Double	NNP	double	double	doubl	N	O
-	:	-	-	-	N	O
Blind	NNP	blind	blind	blind	Y	O
Phase	NNP	phase	phase	phase	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
74	CD	74	74	74	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
34	CD	34	34	34	N	O
)	)	)	)	)	N	O

Subjects	NNS	subjects	subject	subject	N	O

with	IN	with	with	with	N	O
TEAEs	NNP	teaes	teaes	teae	N	O
70%	CD	70%	70%	70%	N	O
62%	CD	62%	62%	62%	N	O

Eye	NNP	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O
38%	CD	38%	38%	38%	N	O
21%	CD	21%	21%	21%	N	O

Eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
ptosis	NN	ptosis	ptosis	ptosi	Y	I-AdverseReaction
19%	CD	19%	19%	19%	N	O
9%	CD	9%	9%	9%	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
eye	NN	eye	eye	eye	N	I-AdverseReaction
16%	CD	16%	16%	16%	N	O
12%	CD	12%	12%	12%	N	O

Visual	JJ	visual	visual	visual	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
12%	CD	12%	12%	12%	N	O
6%	CD	6%	6%	6%	N	O

Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
30%	CD	30%	30%	30%	N	O
15%	CD	15%	15%	15%	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
mouth	VBD	mouth	mouth	mouth	N	I-AdverseReaction
16%	CD	16%	16%	16%	N	O
3%	CD	3%	3%	3%	N	O

Diarrhoea	NNP	diarrhoea	diarrhoea	diarrhoea	Y	B-AdverseReaction
8%	CD	8%	8%	8%	N	O
-	:	-	-	-	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
20%	CD	20%	20%	20%	N	O
15%	CD	15%	15%	15%	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
5%	CD	5%	5%	5%	N	O
3%	CD	3%	3%	3%	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
5%	CD	5%	5%	5%	N	O
3%	CD	3%	3%	3%	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
14%	CD	14%	14%	14%	N	O
9%	CD	9%	9%	9%	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
7%	CD	7%	7%	7%	N	O
3%	CD	3%	3%	3%	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
11%	CD	11%	11%	11%	N	O
9%	CD	9%	9%	9%	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
11%	CD	11%	11%	11%	N	O
3%	CD	3%	3%	3%	N	O

Dyspnoea	NNP	dyspnoea	dyspnoea	dyspnoea	Y	B-AdverseReaction
5%	CD	5%	5%	5%	N	O
3%	CD	3%	3%	3%	N	O

Glabellar	JJ	glabellar	glabellar	glabellar	N	O
Lines	NNS	lines	line	line	N	O

In	IN	in	in	in	N	O

three	CD	three	three	three	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
803	CD	803	803	803	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
glabellar	JJ	glabellar	glabellar	glabellar	N	O
lines	NNS	lines	line	line	N	O
,	,	,	,	,	N	O
535	CD	535	535	535	N	O
subjects	NNS	subjects	subject	subject	N	O
received	VBD	received	received	receiv	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
20	CD	20	20	20	N	O
Units	NNS	units	unit	unit	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
and	CC	and	and	and	N	O
268	CD	268	268	268	N	O
subjects	NNS	subjects	subject	subject	N	O
received	VBN	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

XEOMIN	RB	xeomin	xeomin	xeomin	N	O
treated	VBN	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
24	CD	24	24	24	N	O
to	TO	to	to	to	N	O
74	CD	74	74	74	N	O
years	NNS	years	year	year	N	O
old	JJ	old	old	old	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
female	JJ	female	female	femal	N	O
(	(	(	(	(	N	O
88%	CD	88%	88%	88%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
treated	VBD	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
29	CD	29	29	29	N	O
(	(	(	(	(	N	O
5.4%	CD	5.4%	5.4%	5.4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
facial	JJ	facial	facial	facial	N	B-AdverseReaction
paresis	NN	paresis	paresis	paresi	Y	I-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Four	CD	four	four	four	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
two	CD	two	two	two	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

Six	NNP	six	six	six	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
treated	VBD	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
experienced	VBD	experienced	experienced	experienc	N	O
six	CD	six	six	six	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
assessed	VBN	assessed	assessed	assess	N	O
as	RB	as	a	as	N	O
unrelated	JJ	unrelated	unrelated	unrel	N	O
to	TO	to	to	to	N	O
study	VB	study	study	studi	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
XEOMIN	VB	xeomin	xeomin	xeomin	N	O
with	IN	with	with	with	N	O
glabellar	JJ	glabellar	glabellar	glabellar	N	O
lines	NNS	lines	line	line	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
some	DT	some	some	some	N	O
basis	NN	basis	basis	basi	N	O
to	TO	to	to	to	N	O
believe	VB	believe	believe	believ	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
between	IN	between	between	between	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
XEOMIN	VBP	xeomin	xeomin	xeomin	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
535	CD	535	535	535	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
268	CD	268	268	268	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O

system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
33	CD	33	33	33	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
1	CD	1	1	1	N	O
29	CD	29	29	29	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O

Facial	JJ	facial	facial	facial	N	B-AdverseReaction
paresis	NN	paresis	paresis	paresi	Y	I-AdverseReaction
(	(	(	(	(	N	O
brow	JJ	brow	brow	brow	N	B-AdverseReaction
ptosis	NN	ptosis	ptosis	ptosi	Y	I-AdverseReaction
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
0.7	CD	0.7	0.7	0.7	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
0.9	CD	0.9	0.9	0.9	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0.7	CD	0.7	0.7	0.7	N	O
)	)	)	)	)	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.6	CD	0.6	0.6	0.6	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.2	CD	0.2	0.2	0.2	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Facial	NNP	facial	facial	facial	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.2	CD	0.2	0.2	0.2	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.4	CD	0.4	0.4	0.4	N	O
)	)	)	)	)	N	O

Sensation	NN	sensation	sensation	sensat	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.4	CD	0.4	0.4	0.4	N	O
)	)	)	)	)	N	O

Eye	NNP	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
0.9	CD	0.9	0.9	0.9	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Eyelid	NNP	eyelid	eyelid	eyelid	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0.4	CD	0.4	0.4	0.4	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Blepharospasm	NNP	blepharospasm	blepharospasm	blepharospasm	Y	B-AdverseReaction
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.2	CD	0.2	0.2	0.2	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Eye	NNP	eye	eye	eye	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.2	CD	0.2	0.2	0.2	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
ptosis	NN	ptosis	ptosis	ptosi	Y	I-AdverseReaction
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.2	CD	0.2	0.2	0.2	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

In	IN	in	in	in	N	O
open	JJ	open	open	open	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
multiple	JJ	multiple	multiple	multipl	N	O
dose	NN	dose	dose	dose	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
105	CD	105	105	105	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
800	CD	800	800	800	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
13.1%	CD	13.1%	13.1%	13.1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
,	,	,	,	,	N	O
reported	VBD	reported	reported	report	N	O
for	IN	for	for	for	N	O
57	CD	57	57	57	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
7.1%	CD	7.1%	7.1%	7.1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
followed	VBN	followed	followed	follow	N	O
by	IN	by	by	by	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
in	IN	in	in	in	N	O
8	CD	8	8	8	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
facial	JJ	facial	facial	facial	N	B-AdverseReaction
paresis	NN	paresis	paresis	paresi	Y	I-AdverseReaction
(	(	(	(	(	N	O
brow	JJ	brow	brow	brow	N	B-AdverseReaction
ptosis	NN	ptosis	ptosis	ptosi	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
elevation	NN	elevation	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
eyebrow	NN	eyebrow	eyebrow	eyebrow	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O

Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
proteins	NNS	proteins	protein	protein	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
potential	JJ	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
is	VBZ	is	is	is	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
positivity	NN	positivity	positivity	posit	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
across	IN	across	across	across	N	O
products	NNS	products	product	product	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
class	NN	class	class	class	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O

6.3	CD	6.3	6.3	6.3	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
:	:	:	:	:	N	O
eye	NN	eye	eye	eye	N	B-AdverseReaction
swelling	NN	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
flu	SYM	flu	flu	flu	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
like	IN	like	like	like	N	I-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
allergic	JJ	allergic	allergic	allerg	N	B-AdverseReaction
dermatitis	NN	dermatitis	dermatitis	dermat	Y	I-AdverseReaction
,	,	,	,	,	N	O
localized	VBN	localized	localized	local	N	B-AdverseReaction
allergic	JJ	allergic	allergic	allerg	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
like	IN	like	like	like	N	O
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	I-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	I-AdverseReaction
or	CC	or	or	or	N	O
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
herpes	NNS	herpes	herpes	herp	N	B-AdverseReaction
zoster	NN	zoster	zoster	zoster	N	I-AdverseReaction
,	,	,	,	,	N	O
muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
spasm	NN	spasm	spasm	spasm	N	I-AdverseReaction
,	,	,	,	,	N	O
dysarthria	NN	dysarthria	dysarthria	dysarthria	Y	B-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
DISTANT	NNP	distant	distant	distant	N	B-AdverseReaction
SPREAD	NNP	spread	spread	spread	N	I-AdverseReaction
OF	NNP	of	of	of	N	I-AdverseReaction
TOXIN	NNP	toxin	toxin	toxin	N	I-AdverseReaction
EFFECT	NNP	effect	effect	effect	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
DISTANT	NNP	distant	distant	distant	N	B-AdverseReaction
SPREAD	NNP	spread	spread	spread	N	I-AdverseReaction
OF	NNP	of	of	of	N	I-AdverseReaction
TOXIN	NNP	toxin	toxin	toxin	N	I-AdverseReaction
EFFECT	NNP	effect	effect	effect	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Postmarketing	NNP	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
indicate	VBP	indicate	indicate	indic	N	O
that	IN	that	that	that	N	O
the	DT	the	the	the	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
and	CC	and	and	and	N	O
all	DT	all	all	all	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	B-Factor
spread	VB	spread	spread	spread	N	B-AdverseReaction
from	IN	from	from	from	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
area	NN	area	area	area	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
injection	NN	injection	injection	inject	Y	I-AdverseReaction
to	TO	to	to	to	N	O
produce	VB	produce	produce	produc	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	B-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
may	MD	may	may	may	N	B-Factor
include	VB	include	include	includ	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
generalized	VBN	generalized	generalized	gener	N	B-AdverseReaction
muscle	NN	muscle	muscle	muscl	N	I-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
ptosis	NN	ptosis	ptosis	ptosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysphonia	NN	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysarthria	NN	dysarthria	dysarthria	dysarthria	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
incontinence	NN	incontinence	incontinence	incontin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
breathing	NN	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
hours	NNS	hours	hour	hour	N	O
to	TO	to	to	to	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

Swallowing	VBG	swallowing	swallowing	swallow	N	B-AdverseReaction
and	CC	and	and	and	N	O
breathing	VBG	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
life	NN	life	life	life	N	B-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
and	CC	and	and	and	N	O
there	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
is	VBZ	is	is	is	N	O
probably	RB	probably	probably	probabl	N	O
greatest	JJS	greatest	greatest	greatest	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
but	CC	but	but	but	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
can	MD	can	can	can	N	O
also	RB	also	also	also	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
underlying	JJ	underlying	underlying	underli	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
would	MD	would	would	would	N	O
predispose	VB	predispose	predispose	predispos	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
unapproved	JJ	unapproved	unapproved	unapprov	N	O
uses	NNS	uses	us	use	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
and	CC	and	and	and	N	O
adults	NNS	adults	adult	adult	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
approved	JJ	approved	approved	approv	N	O
indications	NNS	indications	indication	indic	N	O
,	,	,	,	,	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
spread	NN	spread	spread	spread	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
effect	NN	effect	effect	effect	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
comparable	JJ	comparable	comparable	compar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
used	VBN	used	used	use	N	O
to	TO	to	to	to	N	O
treat	VB	treat	treat	treat	N	O
cervical	JJ	cervical	cervical	cervic	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
lower	JJR	lower	lower	lower	N	O
doses	NNS	doses	dos	dose	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
DISTANT	NNP	distant	distant	distant	N	B-AdverseReaction
SPREAD	NNP	spread	spread	spread	N	I-AdverseReaction
OF	NNP	of	of	of	N	I-AdverseReaction
TOXIN	NNP	toxin	toxin	toxin	N	I-AdverseReaction
EFFECT	NNP	effect	effect	effect	N	I-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
and	CC	and	and	and	N	O
all	DT	all	all	all	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	B-Factor
spread	VB	spread	spread	spread	N	B-AdverseReaction
from	IN	from	from	from	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
area	NN	area	area	area	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
injection	NN	injection	injection	inject	Y	I-AdverseReaction
to	TO	to	to	to	N	O
produce	VB	produce	produce	produc	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	B-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
hours	NNS	hours	hour	hour	N	O
to	TO	to	to	to	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

Swallowing	VBG	swallowing	swallowing	swallow	N	B-AdverseReaction
and	CC	and	and	and	N	O
breathing	VBG	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
be	VB	be	be	be	N	O
life	NN	life	life	life	N	B-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
and	CC	and	and	and	N	O
there	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
is	VBZ	is	is	is	N	O
probably	RB	probably	probably	probabl	N	O
greatest	JJS	greatest	greatest	greatest	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
but	CC	but	but	but	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
can	MD	can	can	can	N	O
also	RB	also	also	also	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
underlying	JJ	underlying	underlying	underli	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
would	MD	would	would	would	N	O
predispose	VB	predispose	predispose	predispos	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)\n	RB	)\n	)\n	)\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
For	IN	for	for	for	N	O
All	DT	all	all	all	N	O
Indications	NNS	indications	indication	indic	N	O
:	:	:	:	:	N	O

The	DT	the	the	the	N	O
potency	NN	potency	potency	potenc	N	O
Units	NNP	units	unit	unit	N	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
interchangeable	JJ	interchangeable	interchangeable	interchang	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
preparations	NNS	preparations	preparation	prepar	N	O
of	IN	of	of	of	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
Units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
biological	JJ	biological	biological	biolog	N	O
activity	NN	activity	activity	activ	N	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
or	CC	or	or	or	N	O
converted	VBN	converted	converted	convert	N	O
into	IN	into	into	into	N	O
Units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Immediate	NNP	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
attention	NN	attention	attention	attent	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
required	VBN	required	required	requir	N	O
in	IN	in	in	in	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
speech	NN	speech	speech	speech	N	O
or	CC	or	or	or	N	O
swallowing	VBG	swallowing	swallowing	swallow	N	O
difficulties	NNS	difficulties	difficulty	difficulti	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
compromised	JJ	compromised	compromised	compromis	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
function	NN	function	function	function	N	O
or	CC	or	or	or	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Concomitant	NNP	concomitant	concomitant	concomit	N	O
neuromuscular	JJ	neuromuscular	neuromuscular	neuromuscular	N	O
disorders	NNS	disorders	disorder	disord	N	O
may	MD	may	may	may	N	O
exacerbate	VB	exacerbate	exacerbate	exacerb	N	O
clinical	JJ	clinical	clinical	clinic	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Cervical	JJ	cervical	cervical	cervic	N	O
Dystonia	NNP	dystonia	dystonia	dystonia	Y	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O

Patients	NNS	patients	patient	patient	N	O

with	IN	with	with	with	N	O
smaller	JJR	smaller	smaller	smaller	N	O
neck	NN	neck	neck	neck	N	O
muscle	NN	muscle	muscle	muscl	N	O
mass	NN	mass	mass	mass	Y	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
require	VBP	require	require	requir	N	O
bilateral	JJ	bilateral	bilateral	bilater	N	O
injections	NNS	injections	injection	inject	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
sternocleidomastoid	JJ	sternocleidomastoid	sternocleidomastoid	sternocleidomastoid	N	O
muscles	NNS	muscles	muscle	muscl	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
greater	JJR	greater	greater	greater	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Limiting	VBG	limiting	limiting	limit	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
injected	VBD	injected	injected	inject	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
sternocleidomastoid	JJ	sternocleidomastoid	sternocleidomastoid	sternocleidomastoid	N	O
muscle	NN	muscle	muscle	muscl	N	O
may	MD	may	may	may	N	O
decrease	VB	decrease	decrease	decreas	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	O
.	.	.	.	.	N	O

Blepharospasm	NNP	blepharospasm	blepharospasm	blepharospasm	Y	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O

Corneal	NN	corneal	corneal	corneal	N	B-AdverseReaction

exposure	NN	exposure	exposure	exposur	N	I-AdverseReaction
and	CC	and	and	and	N	O
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction

Injection	NN	injection	injection	inject	Y	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
orbicularis	JJ	orbicularis	orbicularis	orbiculari	N	O
oculi	JJ	oculi	oculus	oculi	N	O
muscle	NN	muscle	muscle	muscl	N	O
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
reduced	VB	reduced	reduced	reduc	N	B-AdverseReaction
blinking	NN	blinking	blinking	blink	N	I-AdverseReaction
and	CC	and	and	and	N	O
corneal	NN	corneal	corneal	corneal	N	B-AdverseReaction
exposure	NN	exposure	exposure	exposur	N	I-AdverseReaction
with	IN	with	with	with	N	O
possible	JJ	possible	possible	possibl	N	B-Factor
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
or	CC	or	or	or	N	O
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
.	.	.	.	.	N	O

Lower	JJR	lower	lower	lower	N	O
lid	JJ	lid	lid	lid	N	O
injections	NNS	injections	injection	inject	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
repeated	VBN	repeated	repeated	repeat	N	O
if	IN	if	if	if	N	O
diplopia	NNS	diplopia	diplopia	diplopia	Y	O
occurred	VBD	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
previous	JJ	previous	previous	previou	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
injections	NNS	injections	injection	inject	N	O
.	.	.	.	.	N	O

Glabellar	JJ	glabellar	glabellar	glabellar	N	O
Lines	NNP	lines	line	line	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O

Risk	NN	risk	risk	risk	N	B-Factor

of	IN	of	of	of	N	O
ptosis	NN	ptosis	ptosis	ptosi	Y	B-AdverseReaction
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.1	CD	5.1	5.1	5.1	N	O

Spread	NN	spread	spread	spread	N	O

of	IN	of	of	of	N	O
Toxin	NNP	toxin	toxin	toxin	N	O
Effect	NNP	effect	effect	effect	N	O

Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
approved	VBD	approved	approved	approv	N	O
botulinum	JJ	botulinum	botulinum	botulinum	N	O
toxins	NNS	toxins	toxin	toxin	N	O
suggest	VBP	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	B-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
be	VB	be	be	be	N	O
observed	VBN	observed	observed	observ	N	O
beyond	IN	beyond	beyond	beyond	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
local	JJ	local	local	local	N	I-AdverseReaction
injection	NN	injection	injection	inject	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
are	VBP	are	are	are	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
of	IN	of	of	of	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
include	VB	include	include	includ	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
generalized	VBN	generalized	generalized	gener	N	B-AdverseReaction
muscle	NN	muscle	muscle	muscl	N	I-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
ptosis	NN	ptosis	ptosis	ptosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysphonia	NN	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysarthria	NN	dysarthria	dysarthria	dysarthria	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
incontinence	NN	incontinence	incontinence	incontin	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
breathing	VBG	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
hours	NNS	hours	hour	hour	N	O
to	TO	to	to	to	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

Swallowing	VBG	swallowing	swallowing	swallow	N	B-AdverseReaction
and	CC	and	and	and	N	O
breathing	VBG	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
be	VB	be	be	be	N	O
life	NN	life	life	life	N	B-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
and	CC	and	and	and	N	O
there	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
spread	NN	spread	spread	spread	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
toxin	NN	toxin	toxin	toxin	N	I-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
is	VBZ	is	is	is	N	O
probably	RB	probably	probably	probabl	N	O
greatest	JJS	greatest	greatest	greatest	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
but	CC	but	but	but	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
underlying	JJ	underlying	underlying	underli	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
would	MD	would	would	would	N	O
predispose	VB	predispose	predispose	predispos	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
unapproved	JJ	unapproved	unapproved	unapprov	N	O
uses	NNS	uses	us	use	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
and	CC	and	and	and	N	O
adults	NNS	adults	adult	adult	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
approved	JJ	approved	approved	approv	N	O
indications	NNS	indications	indication	indic	N	O
,	,	,	,	,	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
consistent	VBP	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
spread	NN	spread	spread	spread	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
toxin	NN	toxin	toxin	toxin	N	I-AdverseReaction
effect	NN	effect	effect	effect	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
comparable	JJ	comparable	comparable	compar	N	O
to	TO	to	to	to	N	O
or	CC	or	or	or	N	O
lower	JJR	lower	lower	lower	N	O
than	IN	than	than	than	N	O
doses	NNS	doses	dos	dose	N	O
used	VBN	used	used	use	N	O
to	TO	to	to	to	N	O
treat	VB	treat	treat	treat	N	O
cervical	JJ	cervical	cervical	cervic	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
or	CC	or	or	or	N	O
caregivers	NNS	caregivers	caregiver	caregiv	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
to	TO	to	to	to	N	O
seek	VB	seek	seek	seek	N	O
immediate	JJ	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
care	NN	care	care	care	N	O
if	IN	if	if	if	N	O
swallowing	NN	swallowing	swallowing	swallow	N	O
,	,	,	,	,	N	O
speech	NN	speech	speech	speech	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
disorders	NNS	disorders	disorder	disord	N	O
occur	VBP	occur	occur	occur	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Lack	NNP	lack	lack	lack	N	O
of	IN	of	of	of	N	O
Interchangeability	NNP	interchangeability	interchangeability	interchang	N	O
between	IN	between	between	between	N	O
Botulinum	NNP	botulinum	botulinum	botulinum	N	O
Toxin	NNP	toxin	toxin	toxin	N	O
Products	NNS	products	product	product	N	O

The	DT	the	the	the	N	O
potency	NN	potency	potency	potenc	N	O
Units	NNP	units	unit	unit	N	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
are	VBP	are	are	are	N	O
specific	JJ	specific	specific	specif	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
preparation	NN	preparation	preparation	prepar	N	O
and	CC	and	and	and	N	O
assay	VB	assay	assay	assay	N	O
method	NN	method	method	method	N	O
utilized	JJ	utilized	utilized	util	N	O
.	.	.	.	.	N	O

They	PRP	they	they	they	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
interchangeable	JJ	interchangeable	interchangeable	interchang	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
other	JJ	other	other	other	N	O
preparations	NNS	preparations	preparation	prepar	N	O
of	IN	of	of	of	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
and	CC	and	and	and	N	O
,	,	,	,	,	N	O
therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
Units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
biological	JJ	biological	biological	biolog	N	O
activity	NN	activity	activity	activ	N	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
or	CC	or	or	or	N	O
converted	VBN	converted	converted	convert	N	O
into	IN	into	into	into	N	O
Units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
assessed	VBN	assessed	assessed	assess	N	O
with	IN	with	with	with	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
specific	JJ	specific	specific	specif	N	O
assay	VBP	assay	assay	assay	N	O
method	JJ	method	method	method	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Description	NNP	description	description	descript	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	B-DrugClass
toxin	NN	toxin	toxin	toxin	N	I-DrugClass
products	NNS	products	product	product	N	I-DrugClass
(	(	(	(	(	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
serum	NN	serum	serum	serum	N	B-AdverseReaction
sickness	NN	sickness	sickness	sick	Y	I-AdverseReaction
,	,	,	,	,	N	O
urticaria	JJ	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
soft	JJ	soft	soft	soft	N	B-AdverseReaction
tissue	NN	tissue	tissue	tissu	N	I-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
serious	JJ	serious	serious	seriou	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
immediate	JJ	immediate	immediate	immedi	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
further	JJ	further	further	further	N	O
injection	NN	injection	injection	inject	Y	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
and	CC	and	and	and	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
therapy	NN	therapy	therapy	therapi	N	O
immediately	RB	immediately	immediately	immedi	N	O
instituted	VBD	instituted	instituted	institut	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	O
and	CC	and	and	and	N	O
Breathing	NNP	breathing	breathing	breath	N	O
Difficulties	NNP	difficulties	difficulty	difficulti	N	O
in	IN	in	in	in	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
Cervical	NNP	cervical	cervical	cervic	N	O
Dystonia	NNP	dystonia	dystonia	dystonia	Y	O

Treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
can	MD	can	can	can	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
swallowing	NN	swallowing	swallowing	swallow	N	B-AdverseReaction
or	CC	or	or	or	N	O
breathing	NN	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
swallowing	NN	swallowing	swallowing	swallow	N	O
or	CC	or	or	or	N	O
breathing	VBG	breathing	breathing	breath	N	O
difficulties	NNS	difficulties	difficulty	difficulti	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
more	RBR	more	more	more	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
complications	NNS	complications	complication	complic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
most	JJS	most	most	most	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
this	DT	this	this	thi	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
consequence	NN	consequence	consequence	consequ	N	O
of	IN	of	of	of	N	O
weakening	NN	weakening	weakening	weaken	N	O
of	IN	of	of	of	N	O
muscles	NNS	muscles	muscle	muscl	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
area	NN	area	area	area	N	O
of	IN	of	of	of	N	O
injection	NN	injection	injection	inject	Y	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
involved	VBN	involved	involved	involv	N	O
in	IN	in	in	in	N	O
breathing	VBG	breathing	breathing	breath	N	O
or	CC	or	or	or	N	O
swallowing	VBG	swallowing	swallowing	swallow	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
distant	JJ	distant	distant	distant	N	O
effects	NNS	effects	effect	effect	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
additional	JJ	additional	additional	addit	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
muscles	NNS	muscles	muscle	muscl	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
involved	VBN	involved	involved	involv	N	O
[	NNP	[	[	[	N	O
See	NNP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Deaths	NNS	deaths	death	death	N	B-AdverseReaction
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
complication	NN	complication	complication	complic	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	B-Severity
dysphagia	NNS	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	B-DrugClass
toxin	NN	toxin	toxin	toxin	N	I-DrugClass
.	.	.	.	.	N	O

Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
may	MD	may	may	may	N	O
persist	VB	persist	persist	persist	N	O
for	IN	for	for	for	N	O
several	JJ	several	several	sever	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
require	VBP	require	require	requir	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
feeding	NN	feeding	feeding	feed	N	O
tube	NN	tube	tube	tube	N	O
to	TO	to	to	to	N	O
maintain	VB	maintain	maintain	maintain	N	O
adequate	JJ	adequate	adequate	adequ	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
and	CC	and	and	and	N	O
hydration	NN	hydration	hydration	hydrat	N	O
.	.	.	.	.	N	O

Aspiration	NN	aspiration	aspiration	aspir	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
from	IN	from	from	from	N	O
severe	JJ	severe	severe	sever	N	B-Severity
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
particular	JJ	particular	particular	particular	N	O
risk	NN	risk	risk	risk	N	O
when	WRB	when	when	when	N	O
treating	VBG	treating	treating	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
whom	WP	whom	whom	whom	N	O
swallowing	VBG	swallowing	swallowing	swallow	N	O
or	CC	or	or	or	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	O
function	NN	function	function	function	N	O
is	VBZ	is	is	is	N	O
already	RB	already	already	alreadi	N	O
compromised	VBN	compromised	compromised	compromis	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
cervical	JJ	cervical	cervical	cervic	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	B-DrugClass
toxins	NNS	toxins	toxin	toxin	N	I-DrugClass
may	MD	may	may	may	N	O
weaken	VB	weaken	weaken	weaken	N	B-AdverseReaction
neck	NN	neck	neck	neck	N	I-AdverseReaction
muscles	NNS	muscles	muscle	muscl	N	I-AdverseReaction
that	WDT	that	that	that	N	O
serve	VBP	serve	serve	serv	N	O
as	IN	as	a	as	N	O
accessory	JJ	accessory	accessory	accessori	N	O
muscles	NNS	muscles	muscle	muscl	N	O
of	IN	of	of	of	N	O
ventilation	NN	ventilation	ventilation	ventil	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
critical	JJ	critical	critical	critic	N	B-Severity
loss	NN	loss	loss	loss	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
breathing	VBG	breathing	breathing	breath	N	I-AdverseReaction
capacity	NN	capacity	capacity	capac	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	O
disorders	NNS	disorders	disorder	disord	N	O
who	WP	who	who	who	N	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
become	VBN	become	become	becom	N	O
dependent	JJ	dependent	dependent	depend	N	O
upon	IN	upon	upon	upon	N	O
these	DT	these	these	these	N	O
accessory	JJ	accessory	accessory	accessori	N	O
muscles	NNS	muscles	muscle	muscl	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
post	VBN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
breathing	VBG	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
cervical	JJ	cervical	cervical	cervic	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	B-DrugClass
toxin	NN	toxin	toxin	toxin	N	I-DrugClass
products	NNS	products	product	product	N	I-DrugClass
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
smaller	JJR	smaller	smaller	smaller	N	O
neck	NN	neck	neck	neck	N	O
muscle	NN	muscle	muscle	muscl	N	O
mass	NN	mass	mass	mass	Y	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
require	VBP	require	require	requir	N	O
bilateral	JJ	bilateral	bilateral	bilater	N	O
injections	NNS	injections	injection	inject	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
sternocleidomastoid	NN	sternocleidomastoid	sternocleidomastoid	sternocleidomastoid	N	O
muscles	NNS	muscles	muscle	muscl	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
greater	JJR	greater	greater	greater	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
general	JJ	general	general	gener	N	O
,	,	,	,	,	N	O
limiting	VBG	limiting	limiting	limit	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
injected	VBD	injected	injected	inject	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
sternocleidomastoid	JJ	sternocleidomastoid	sternocleidomastoid	sternocleidomastoid	N	O
muscle	NN	muscle	muscle	muscl	N	O
may	MD	may	may	may	N	O
decrease	VB	decrease	decrease	decreas	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
immediate	JJ	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
attention	NN	attention	attention	attent	N	O
should	MD	should	should	should	N	O
they	PRP	they	they	they	N	O
develop	VB	develop	develop	develop	N	O
problems	NNS	problems	problem	problem	N	O
with	IN	with	with	with	N	O
swallowing	NN	swallowing	swallowing	swallow	N	O
,	,	,	,	,	N	O
speech	NN	speech	speech	speech	N	O
or	CC	or	or	or	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
disorders	NNS	disorders	disorder	disord	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
within	IN	within	within	within	N	O
hours	NNS	hours	hour	hour	N	O
to	TO	to	to	to	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
injection	NN	injection	injection	inject	Y	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
[	NNP	[	[	[	N	O
See	NNP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Pre	NNP	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
Neuromuscular	JJ	neuromuscular	neuromuscular	neuromuscular	N	O
Disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
Special	JJ	special	special	special	N	O
Populations	NNS	populations	population	popul	N	O

Individuals	NNS	individuals	individual	individu	N	O
with	IN	with	with	with	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	O
motor	NN	motor	motor	motor	N	O
neuropathic	JJ	neuropathic	neuropathic	neuropath	N	O
diseases	NNS	diseases	disease	diseas	N	O
,	,	,	,	,	N	O
amyotrophic	JJ	amyotrophic	amyotrophic	amyotroph	N	O
lateral	JJ	lateral	lateral	later	N	O
sclerosis	NN	sclerosis	sclerosis	sclerosi	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
neuromuscular	JJ	neuromuscular	neuromuscular	neuromuscular	N	O
junctional	NN	junctional	junctional	junction	N	O
disorders	NNS	disorders	disorder	disord	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
myasthenia	JJ	myasthenia	myasthenia	myasthenia	Y	O
gravis	NN	gravis	gravis	gravi	N	O
or	CC	or	or	or	N	O
Lambert	NNP	lambert	lambert	lambert	N	O
-	:	-	-	-	N	O
Eaton	NNP	eaton	eaton	eaton	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
particularly	RB	particularly	particularly	particularli	N	O
closely	RB	closely	closely	close	N	O
when	WRB	when	when	when	N	O
given	VBN	given	given	given	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
neuromuscular	JJ	neuromuscular	neuromuscular	neuromuscular	N	O
disorders	NNS	disorders	disorder	disord	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	JJ	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
effects	NNS	effects	effect	effect	N	O
including	VBG	including	including	includ	N	O
severe	JJ	severe	severe	sever	N	B-Severity
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
compromise	NN	compromise	compromise	compromis	N	I-AdverseReaction
from	IN	from	from	from	N	O
typical	JJ	typical	typical	typic	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
[	NNP	[	[	[	N	O
See	NNP	see	see	see	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Corneal	NNP	corneal	corneal	corneal	N	O
Exposure	NNP	exposure	exposure	exposur	N	O
,	,	,	,	,	N	O
Corneal	NNP	corneal	corneal	corneal	N	O
Ulceration	NNP	ulceration	ulceration	ulcer	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Ectropion	NNP	ectropion	ectropion	ectropion	Y	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
Treated	NNP	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
for	IN	for	for	for	N	O
Blepharospasm	NNP	blepharospasm	blepharospasm	blepharospasm	Y	O

Reduced	VBN	reduced	reduced	reduc	N	B-AdverseReaction
blinking	NN	blinking	blinking	blink	N	I-AdverseReaction
from	IN	from	from	from	N	O
injection	NN	injection	injection	inject	Y	O
of	IN	of	of	of	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	B-DrugClass
toxin	NN	toxin	toxin	toxin	N	I-DrugClass
products	NNS	products	product	product	N	I-DrugClass
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
orbicularis	JJ	orbicularis	orbicularis	orbiculari	N	O
muscle	NN	muscle	muscle	muscl	N	O
can	MD	can	can	can	N	O
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
corneal	VB	corneal	corneal	corneal	N	B-AdverseReaction
exposure	NN	exposure	exposure	exposur	N	I-AdverseReaction
,	,	,	,	,	N	O
persistent	JJ	persistent	persistent	persist	N	I-AdverseReaction
epithelial	JJ	epithelial	epithelial	epitheli	N	I-AdverseReaction
defect	NN	defect	defect	defect	N	I-AdverseReaction
and	CC	and	and	and	N	O
corneal	JJ	corneal	corneal	corneal	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
VII	NNP	vii	vii	vii	N	O
nerve	NN	nerve	nerve	nerv	N	O
disorders	NNS	disorders	disorder	disord	N	O
.	.	.	.	.	N	O

Careful	JJ	careful	careful	care	N	O
testing	NN	testing	testing	test	N	O
of	IN	of	of	of	N	O
corneal	JJ	corneal	corneal	corneal	N	O
sensation	NN	sensation	sensation	sensat	N	O
in	IN	in	in	in	N	O
eyes	NNS	eyes	eye	eye	N	O
previously	RB	previously	previously	previous	N	O
operated	VBD	operated	operated	oper	N	O
upon	NN	upon	upon	upon	N	O
,	,	,	,	,	N	O
avoidance	NN	avoidance	avoidance	avoid	N	O
of	IN	of	of	of	N	O
injection	NN	injection	injection	inject	Y	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
lower	JJR	lower	lower	lower	N	O
lid	JJ	lid	lid	lid	N	O
area	NN	area	area	area	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
ectropion	NN	ectropion	ectropion	ectropion	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vigorous	JJ	vigorous	vigorous	vigor	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
epithelial	JJ	epithelial	epithelial	epitheli	N	O
defect	NN	defect	defect	defect	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
employed	VBN	employed	employed	employ	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
protective	JJ	protective	protective	protect	N	O
drops	NNS	drops	drop	drop	N	O
,	,	,	,	,	N	O
ointment	NN	ointment	ointment	ointment	N	O
,	,	,	,	,	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
soft	JJ	soft	soft	soft	N	O
contact	NN	contact	contact	contact	N	O
lenses	NNS	lenses	lens	lens	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
closure	NN	closure	closure	closur	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
eye	NN	eye	eye	eye	N	O
by	IN	by	by	by	N	O
patching	VBG	patching	patching	patch	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
means	NNS	means	mean	mean	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
its	PRP$	its	it	it	N	O
anticholinergic	JJ	anticholinergic	anticholinergic	anticholinerg	N	O
effects	NNS	effects	effect	effect	N	O
,	,	,	,	,	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
narrow	JJ	narrow	narrow	narrow	N	O
angle	NN	angle	angle	angl	N	O
glaucoma	NN	glaucoma	glaucoma	glaucoma	Y	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
prevent	VB	prevent	prevent	prevent	N	O
ectropion	NN	ectropion	ectropion	ectropion	Y	O
,	,	,	,	,	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
injected	VBN	injected	injected	inject	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
medial	JJ	medial	medial	medial	N	O
lower	JJR	lower	lower	lower	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	O
area	NN	area	area	area	N	O
.	.	.	.	.	N	O

Ecchymosis	NNP	ecchymosis	ecchymosis	ecchymosi	Y	O
easily	RB	easily	easily	easili	N	O
occurs	VBZ	occurs	occurs	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
soft	JJ	soft	soft	soft	N	O
tissues	NNS	tissues	tissue	tissu	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
eyelid	NN	eyelid	eyelid	eyelid	N	O
.	.	.	.	.	N	O

Immediate	NNP	immediate	immediate	immedi	N	O
gentle	JJ	gentle	gentle	gentl	N	O
pressure	NN	pressure	pressure	pressur	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
injection	NN	injection	injection	inject	Y	O
site	NN	site	site	site	N	O
can	MD	can	can	can	N	O
limit	VB	limit	limit	limit	N	O
that	DT	that	that	that	N	O
risk	NN	risk	risk	risk	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Ptosis	NNP	ptosis	ptosis	ptosi	Y	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
Treated	NNP	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
for	IN	for	for	for	N	O
Glabellar	NNP	glabellar	glabellar	glabellar	N	O
Lines	NNS	lines	line	line	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
exceed	VB	exceed	exceed	exceed	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
dosage	NN	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
XEOMIN	NNP	xeomin	xeomin	xeomin	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
order	NN	order	order	order	N	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
complication	NN	complication	complication	complic	N	O
of	IN	of	of	of	N	O
ptosis	NN	ptosis	ptosis	ptosi	Y	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
steps	NNS	steps	step	step	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
taken	VBN	taken	taken	taken	N	O
:	:	:	:	:	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
injection	NN	injection	injection	inject	Y	O
near	IN	near	near	near	N	O
the	DT	the	the	the	N	O
levator	NN	levator	levator	levat	N	O
palpebrae	NN	palpebrae	palpebrae	palpebra	N	O
superioris	NN	superioris	superioris	superiori	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
larger	JJR	larger	larger	larger	N	O
brow	NN	brow	brow	brow	N	O
depressor	NN	depressor	depressor	depressor	N	O
complexes	NNS	complexes	complex	complex	N	O
.	.	.	.	.	N	O

Corrugator	NNP	corrugator	corrugator	corrug	N	O
injections	NNS	injections	injection	inject	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
placed	VBN	placed	placed	place	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
cm	NNS	cm	cm	cm	N	O
above	IN	above	above	abov	N	O
the	DT	the	the	the	N	O
bony	NN	bony	bony	boni	N	O
supraorbital	JJ	supraorbital	supraorbital	supraorbit	N	O
ridge	NN	ridge	ridge	ridg	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Human	NNP	human	human	human	N	O
Albumin	NNP	albumin	albumin	albumin	Y	O
and	CC	and	and	and	N	O
Transmission	NNP	transmission	transmission	transmiss	N	O
of	IN	of	of	of	N	O
Viral	NNP	viral	viral	viral	N	O
Diseases	NNP	diseases	disease	diseas	N	O

This	DT	this	this	thi	N	O

product	NN	product	product	product	N	O
contains	VBZ	contains	contains	contain	N	O
albumin	JJ	albumin	albumin	albumin	Y	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
derivative	NN	derivative	derivative	deriv	N	O
of	IN	of	of	of	N	O
human	JJ	human	human	human	N	O
blood	NN	blood	blood	blood	N	O
.	.	.	.	.	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
effective	JJ	effective	effective	effect	N	O
donor	NN	donor	donor	donor	N	O
screening	NN	screening	screening	screen	N	O
and	CC	and	and	and	N	O
product	NN	product	product	product	N	O
manufacturing	NN	manufacturing	manufacturing	manufactur	N	O
processes	VBZ	processes	process	process	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
carries	VBZ	carries	carry	carri	N	O
an	DT	an	an	an	N	O
extremely	RB	extremely	extremely	extrem	N	O
remote	JJ	remote	remote	remot	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
transmission	NN	transmission	transmission	transmiss	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
viral	JJ	viral	viral	viral	N	I-AdverseReaction
diseases	NNS	diseases	disease	diseas	N	I-AdverseReaction
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
theoretical	JJ	theoretical	theoretical	theoret	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
transmission	NN	transmission	transmission	transmiss	N	O
of	IN	of	of	of	N	O
Creutzfeldt	NNP	creutzfeldt	creutzfeldt	creutzfeldt	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Jakob	NNP	jakob	jakob	jakob	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
(	(	(	(	(	N	O
CJD	NNP	cjd	cjd	cjd	Y	B-AdverseReaction
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
also	RB	also	also	also	N	O
considered	VBN	considered	considered	consid	N	O
extremely	RB	extremely	extremely	extrem	N	O
remote	JJ	remote	remote	remot	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
transmission	NN	transmission	transmission	transmiss	N	O
of	IN	of	of	of	N	O
viral	JJ	viral	viral	viral	N	O
diseases	NNS	diseases	disease	diseas	N	O
or	CC	or	or	or	N	O
CJD	NNP	cjd	cjd	cjd	Y	O
have	VBP	have	have	have	N	O
ever	RB	ever	ever	ever	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
albumin	NN	albumin	albumin	albumin	Y	O
.	.	.	.	.	N	O

